Information Provided By:
Fly News Breaks for July 23, 2019
VIVE
Jul 23, 2019 | 08:04 EDT
Maxim analyst Anthony Vendetti downgraded Viveve to Hold from Buy after the company's trial of its CMRF technology did not achieve statistical significance in the intent-to-treat-population of a stress urinary incontinence study.
News For VIVE From the Last 2 Days
There are no results for your query VIVE